Articles related to DRUG SAFETY & INTERACTIONS

Breckenridge Pharmaceutical initiated a voluntary Class II recall of duloxetine delayed-release capsules 60 mg (Lot 241069C, expiration May 31, 2027) on April 21, 2026, following detection of elevated N-nitroso-duloxetine impurity levels attributed to CGMP deviations at the Barcelona manufacturing site, affecting 165,761 bottles distributed nationwide.

Sedative-hypnotic drug effects vary with meal timing, metabolism, and drug half-life in patients with insomnia. These pharmacologic factors influence sleep onset and maintenance, particularly in patients with psychiatric comorbidities requiring concurrent medications.

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.

Vitreoretinal surgeons describe off-label fibrin glue application as a localized tamponade alternative for rhegmatogenous retinal detachment repair, hemorrhage control, and retinal edge stabilization in cases where gas or silicone oil poses prohibitive patient or logistical constraints.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.